Dr. Zurita-Saavedra on Augmenting Therapy Earlier in Prostate Cancer Treatment Journey

Partner | Cancer Centers | <b>MD Anderson</b>

Amado J. Zurita-Saavedra, MD, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Amado J. Zurita-Saavedra, MD, assistant professor, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential benefits of augmenting therapy earlier on in the treatment of patients with newly diagnosed metastatic prostate cancer.

Augmenting therapy for patients with prostate cancer should be strongly considered, according to Zurita-Saavedra. Earlier intensified therapy with androgen-signaling blockade or chemotherapy could benefit these patients, particularly those with high-volume or high-risk disease, Zurita-Saavedra explains.

Reservations exist with augmenting treatment earlier rather than later in patients with prostate cancer, Zurita-Saavedra adds, and this has led to a delay in community and private practices to apply this approach to care, Zurita-Saavedra adds. However, some studies have produced compelling data that have indicated that augmenting therapy early on has helped patients with prostate cancer, Zurita-Saavedra concludes.